Immunexpress is a privately owned company creating revolutionary molecular diagnostics for sepsis. The company has offices in Seattle, USA and Brisbane, Australia. Immunexpress's product pipeline aims to address the overwhelming unmet clinical needs of sepsis patients, as well as clinicians, payers and healthcare systems.
Unlike the traditional approach to sepsis diagnosis, SeptiCyte® quantifies the specific molecular biomarkers from a patient's immune system ('host response'). Biomarkers capture signals from a patient's immune system in response to infection. These biomarkers may hold the key to early detection of sepsis, as well as guiding the use and timing of drugs and other therapies.
Company Details
- Employees
- 15
- Founded
- -
- Address
- 425 Pontius Ave N,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://immunexpress.com
- HQ
- Seattle, Washington
Immunexpress Inc. Questions
Immunexpress Inc.'s website is http://immunexpress.com
Immunexpress Inc.'s LinkedIn profile is https://www.linkedin.com/company/immunexpress-inc
Immunexpress Inc. has
15 employees.
View email and phone details for 15
employees at Immunexpress Inc..
Immunexpress Inc.'s industry is
Biotechnology Research
Immunexpress Inc.'s top competitors are
Inflammatix, Inc.,
Immunext,
Virax Biolabs,
Oisin Biotechnologies,
Pai Life Sciences Inc.,
Biocartis,
Cytovale,
4tissue,
Abacus Dx,
Midiagnostics.
Immunexpress Inc.'s categories are Biotechnology Research
Immunexpress Inc.'s founding year is 2006
